Australian-based biopharmaceutical firm EnGeneIC has begun dosing patients in a Phase I clinical trial of its EDV nanocells for the treatment of recurrent glioblastoma multiforme (GBM) within adults in the US.

EDV nanocells are bacterially derived cells designed as a nanoparticle drug, siRNA or miRNA delivery platform to destroy tumour cells, as well as induce the immune system's anti-tumour response.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The open-label, two-part Cerebral EDV Phase I trial will assess the nanocells in around 20 patients who have already received first-line chemotherapy.

EnGeneIC joint-chief executive officer and director Himanshu Brahmbhatt said: "The EDV nanocells bypass the blood brain barrier (BBB), get into the brain tumour via the tumour-associated leaky blood vessels and then deliver the toxic payload in therapeutically significant concentrations inside the cancer cells.

"We call our EDV platform a cyto-immuno-therapeutic, since it not only directly targets and kills cancer cells but also stimulates the patient's immune system to 'wake up' and fight the tumour."

"This allows us to send potent drugs directly into brain cancer cells and in previous trials we have witnessed minimal to no toxicity in patients.

See Also:

"We call our EDV platform a cyto-immuno-therapeutic, since it not only directly targets and kills cancer cells but also stimulates the patient's immune system to 'wake up' and fight the tumour."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dose exploration part of the trial will evaluate the safety of multiple (EGFR)-EDV-doxorubicin doses at two dose levels, given once per week for seven weeks.

The trial's second part will establish the recommended Phase II dose of (EGFR)-EDV-doxorubicin.

The primary objective of the trial is to determine the safety of the therapy, while the secondary endpoints are measurement of anti-tumour response rates, overall survival, and the recommended Phase II dose determination.

The trial will also examine the biomarkers related to immunotherapy aspects of (EGFR)-EDV-doxorubicin.